SynthesisTheScientificWorldJournal2014
New onset of dermatomyositis/polymyositis during anti-TNF-α therapies: a systematic literature review.
Synthesis in TheScientificWorldJournal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 81 citations in OpenAlex.
- Different age, different phenotype: a comparative analysis of juvenile and adult-onset dermatomyositis from a tertiary centre.Rheumatology (Oxford, England) · 2026Article
- Elevated serum TNF-α in patients with immune-mediated necrotizing myopathy correlates with muscle damage.BMC immunology · 2026Article
- Myositis Mimics: Recognizing Red Flags and Diagnostic Pitfalls.Current rheumatology reports · 2026Review
- Overlap Myositis in a Patient With Psoriasis Treated With Anti-TNF-Alpha Therapy: A Case Report and Review of Literature.Case reports in rheumatology · 2026Article
- Associations between TNF gene promoter variants (rs361525, rs1800629, rs1799964, rs1799724) and the clinical course of idiopathic inflammatory myopathies.Scientific reports · 2025Article
- Antisynthetase Syndrome during anti-TNF-alpha Therapy: Report of Two Cases.Journal of clinical immunology · 2025Article
- Effects of Vitamin D, Infliximab, and Leflunomide on Isolated Rat Striated Muscle with Electrical and Mechanical Stimuli in Statin-Induced Rhabdomyopathy.Journal of clinical practice and research · 2025Article
- Treatment Algorithms for Inflammatory Myopathies in Adults: from Guidelines to Clinical Practice.Current treatment options in rheumatology · 2025Article
- Macrophage involvement in idiopathic inflammatory myopathy: pathogenic mechanisms and therapeutic prospects.Journal of inflammation (London, England) · 2024Review
- Biologic drugs in the treatment of juvenile dermatomyositis: a literature review.Clinical rheumatology · 2024Review
- The Role of Environmental Factors in the Development of Idiopathic Inflammatory Myopathies: a Narrative Review.Current rheumatology reports · 2023Review
- Overlap of dermatomyositis and cutaneous lupus erythematosus: A case series.JAAD case reports · 2023Article
- Occurrence of proliferative myositis after COVID-19 vaccination: A case report.Radiology case reports · 2023Article
- Focus on Anti-Tumour Necrosis Factor (TNF)-α-Related Autoimmune Diseases.International journal of molecular sciences · 2023Review
- Biological Therapies in Inflammatory Myopathies.Rambam Maimonides medical journal · 2023Review
- Coexpression network analysis coupled with connectivity map database mining reveals novel genetic biomarkers and potential therapeutic drugs for polymyositis.Clinical rheumatology · 2022Article
- A novel model of dermatomyositis induced by membrane antigen and calciphylaxis in rats.Biomedical reports · 2022Article
- Antibody Therapies in Autoimmune Inflammatory Myopathies: Promising Treatment Options.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Review
- Inflammatory myopathy occurring shortly after severe acute respiratory syndrome coronavirus 2 vaccination: two case reports.Journal of medical case reports · 2022Article
- High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients.Inflammatory intestinal diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We performed a systematic search of databases from 1990 to 2013 to identify articles concerning the new onset of dermatomyositis/polymyositis (DM/PM) in patients treated with anti-TNF-α therapy. We retrieved 13 publications describing 20 patients where the new onset of DM/PM after anti-TNF-α therapy was recorded. 17 patients were affected by rheumatoid arthritis (RA), one by Crohn's disease, one by ankylosing spondilytis, and one by seronegative arthritis. In 91% of the cases antinuclear autoantibodies were detected after the introduction of anti-TNF-α therapy. In 6 patients antisynthetase antibodies were detected and other clinical findings as interstitial lung disease (ILD) were recorded. Improvement of DM/PM after anti-TNF suspension (with the concomitant use of other immunosuppressors) was recorded in 94% of cases. The emergence of DM/PM and antisynthetase syndrome seem to be associated with the use of anti-TNF-α agents, especially in patients with chronic inflammatory diseases (mainly RA) with positive autoantibodies before therapy initiation. In particular, physicians should pay attention to patients affected by RA with positive antisynthetase antibodies and/or history of ILD. In those cases, the use of the TNF-α blocking agents may trigger the onset of PM/DM or antisynthetase syndrome or may aggravate/trigger the lung disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.